Shaanxi Mei Bang Pharmaceutical Group Co.,Ltd. (605033.SH) disclosed its 2025 interim report. During the reporting period, the company achieved revenue of 485 million yuan, representing a year-over-year decrease of 4.76%; net profit attributable to the parent company was 36.14 million yuan, down 23.81% year-over-year; non-GAAP net profit reached 31.65 million yuan, declining 15.09% year-over-year; basic earnings per share stood at 0.27 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments